Josep Tabernero
MD, PhD
Head, Medical Oncology
👥Biography 个人简介
Prof. Josep Tabernero is a GI oncologist at VHIO who has contributed to the clinical development of ramucirumab, an anti-VEGFR2 antibody, in gastric cancer. He was involved in the REGARD and RAINBOW phase III trials establishing ramucirumab as a standard second-line option for advanced gastric/GEJ adenocarcinoma. His broader research on combining anti-VEGFR2 therapy with chemotherapy and immunotherapy has shaped multi-line anti-angiogenic treatment strategies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Josep Tabernero 的研究动态
Follow Josep Tabernero's research updates
留下邮箱，当我们发布与 Josep Tabernero（Vall d'Hebron University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment